A Wellness Prescription for Parkinson's: Mid to Late-Stage Disease

Pontone, Gregory M.; McDaniels, Bradley; Keener, Adrienne M.; Subramanian, Indu

doi:10.1016/j.jagp.2023.02.049

Cited by 4 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We should recognize that the relationship between pain and constipation likely involves a complex interplay of multiple factors, also including phycological aspects. Thus, actions aiming at restoring well-being in a patient-centered proactive strategy, by promoting physical activity, dietary habits, and by managing anxiety and depression, may all potentially affect HRQoL, reducing psychosocial distress (Schirinzi et al 2019 , 2020 ; Pontone et al 2023 ). These are all recognised factors that deserve further exploration in future studies.…”

Section: Discussionmentioning

confidence: 99%

Constipation and pain in Parkinson’s disease: a clinical analysis

Al-Wardat,

Grillo,

Schirinzi

et al. 2023

J Neural Transm

View full text Add to dashboard Cite

Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by both motor and non-motor symptoms (NMS). Among NMS, constipation and pain are both highly prevalent and debilitating affecting up to 80% of PD patients and impairing their quality of life. Here, we investigated the relationship between constipation and pain in PD patients. This is a retrospective study assessing the relationship between pain and constipation in a PD patient population from a clinical database of patients attending the outpatient clinic of the movement disorders division, Neurology Unit of Policlinico Tor Vergata, in Rome. Subjects were assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, Hoehn and Yahr (H&Y) stage, King’s Parkinson’s Disease Pain Scale (KPPS), Brief Pain Inventory (BPI), Non-Motor Symptoms Scale (NMSS) and Beck Depression Inventory (BDI). Patients were further divided in two groups (Group 1, 32 patients with constipation and Group 2, 35 PD patients without constipation) ANOVA and ANCOVA analysis were used to compare the two groups. PD patients with constipation had significantly higher pain severity and pain interference, as measured by the BPI scale and higher total KPPS score, fluctuation-related pain, nocturnal pain, and radicular pain when compared to PD patients without constipation. This study highlights for the first time a possible interplay between constipation and pain in PD that deserves further investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Constipation and pain in Parkinson’s disease: a clinical analysis

Al-Wardat,

Grillo,

Schirinzi

et al. 2023

J Neural Transm

View full text Add to dashboard Cite

show abstract

“…Preventive therapies help in maintaining good physical and mental health by suggesting some diet and lifestyle changes, exercises, and increased activities of the affected part [29,59,[62][63][64][65][66]. It further intensifies brain communication and nerve functions.…”

Section: Alternative Therapiesmentioning

confidence: 99%

Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms

Indu,

Dimri

2024

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Parkinson's disease (PD) is the second most prevalent neurodegenerative ailment affecting aged people. Several motor and non-motor symptoms appearing with this disease are linked to reduction in dopamine levels. Parkinson’s disease manifested by a wide range of symptoms, including gait instability, voice impairments, bradykinesia, hypomimia, tremors, and cognitive dysfunctions, where the concern is its steady global progression. Therefore, by evaluating the stage-specific retention and transition thresholds, the suggested work attempts to detect the progression of PD. Similarly, the assessment of the annual rate of deterioration of symptoms aids in assessing the influence of medications on four stages and six prime symptoms. Results During the 9-year period following clinical diagnosis, a symptomatic deterioration of 34.995% is observed in untreated patients compared to treated patients. Furthermore, the experimental analysis illustrates that medicines assist in regulating only bradykinesia, tremors, hypomimia, and speech impairment, which lasts for 4.8 years on average. A saturation period is also identified during the moderate phase, where the computed average depreciation in the Unified Parkinson’s Disease Rating Scale (UPDRS) is the least. Similarly, from stages 1 to 4, medicines might improve stage retention by 4.44, 3.5, 2.72, and 1.6 years, respectively. It demonstrates that, despite transient advantages and adverse effects, medications also have an optimistic impact on PD patients. Conclusions Here, we show that medication can extend the lifespan of PD patients up to 12 years cumulatively. Furthermore, the proposed work suggests that stagewise alternative remedies for improving quality of life, boosting the benefits of medicines, and eliminating their side effects. These include counselling, diet changes, yoga asanas, herbal medicines, bio-cleansing and other therapies. The current work does not consider the temporary transition among stages; nonetheless, further investigation regarding PD could open avenues for more worthy treatments with fewer side effects.

show abstract

Psychosocial Challenges Associated with Parkinson’s Disease

McDaniels,

Subramanian

2024

Handbook of the Behavior and Psychology of Disease

View full text Add to dashboard Cite

A Wellness Prescription for Parkinson's: Mid to Late-Stage Disease

Cited by 4 publications

References 62 publications

Constipation and pain in Parkinson’s disease: a clinical analysis

Constipation and pain in Parkinson’s disease: a clinical analysis

Customized treatment for Parkinson’s disease: extending lifespan and improving symptoms

Psychosocial Challenges Associated with Parkinson’s Disease

Contact Info

Product

Resources

About